Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer

The primary objective of this study is to evaluate the efficacy of **pembrolizumab** as a maintenance treatment at usual or low doses in patients with metastatic non-squamous lung cancer. This investigation is clinically relevant as it aims to determine whether a reduced dosage of pembrolizumab can maintain therapeutic effectiveness, potentially minimizing side effects and healthcare costs while preserving patient outcomes.

The clinical trial focuses on the **maintenance treatment in metastatic non-squamous lung cancer**. The study population includes both male and female participants, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any specific mention of lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed detailed inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the efficacy of **maintenance treatment** in patients with metastatic non-squamous lung cancer. This study is structured as a non-inferiority trial, comparing the effects of pembrolizumab administered at usual versus low doses. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from March 1, 2023, to March 31, 2029, allowing for comprehensive data collection and analysis over a six-year period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to determine eligibility based on predefined criteria. Following successful inclusion, participants will be randomly assigned to one of the treatment groups. Regular follow-up visits will be scheduled to monitor the participants' health status, treatment adherence, and any adverse events. These visits are crucial for assessing the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the long-term effects of the treatment.

The expected length of participant involvement in the trial is contingent upon individual response to treatment and overall health status. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or if the principal investigator deems it necessary for their safety. The trial's methodology and design are meticulously crafted to ensure the collection of robust and meaningful data, contributing to the understanding of pembrolizumab's role in the maintenance treatment of metastatic non-squamous lung cancer.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under Phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effects in a larger population. The trial is scheduled to commence recruitment on March 1, 2023, with an estimated completion date of March 31, 2029. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to evaluate the treatment's impact on the targeted medical condition. The absence of explicit endpoints suggests that the trial may employ a range of assessment tools and methodologies to capture comprehensive efficacy data over the study period. The trial's extended duration underscores a commitment to thorough efficacy evaluation, potentially involving multiple timepoints and diverse data sources to ensure robust and reliable outcomes.